<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04315181</url>
  </required_header>
  <id_info>
    <org_study_id>46591</org_study_id>
    <nct_id>NCT04315181</nct_id>
  </id_info>
  <brief_title>Prescription Medication Interactions</brief_title>
  <official_title>Prescription Medications: Pharmacodynamics and Interaction Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sharon Walsh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the effects of doses of opioid/placebo and doses of sedative/placebo,
      alone and in combination. The primary outcomes are related to pharmacodynamic measures
      (subjective ratings of drug liking and other abuse-related effects; physiological outcomes)
      to determine the interaction effects of these compounds.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This is a randomized, double-blind, double-dummy, placebo- controlled design</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Subject-Rated Outcomes</measure>
    <time_frame>These outcomes (visual analog scores, scale of 0-100) will be recorded prior to and in regular intervals after drug administration for the duration of the session (approx. 8 hours per session).</time_frame>
    <description>Participants will rate their subjective drug effects (ex: drug liking, high) on standardized VAS scales.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Oxygen Saturation</measure>
    <time_frame>Oxygen saturation will be recorded prior to and in regular intervals after drug administration for the duration of the session (approx. 8 hours per session).</time_frame>
    <description>Oxygen saturation (measured as a percentage) will be monitored throughout each session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Respiration Rate</measure>
    <time_frame>Respiration rate will be recorded prior to and in regular intervals after drug administration for the duration of the session (approx. 8 hours per session).</time_frame>
    <description>Respiration rate (number of breaths per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood pressure</measure>
    <time_frame>Blood pressure will be recorded prior to and in regular intervals after drug administration for the duration of the session (approx. 8 hours per session).</time_frame>
    <description>Systolic and diastolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Opioid Use</condition>
  <condition>Sedative Use</condition>
  <arm_group>
    <arm_group_label>Oral opioid agonist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive non-therapeutic experimental doses of active or placebo oral opioid agonist. Active opioid agonist/placebo will be administered once per session and will be administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral sedative</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive non-therapeutic experimental doses of active or placebo oral sedative. Active sedative/placebo will be administered once per session and will be administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Opioid agonist/sedative</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive non-therapeutic, experimental doses of active opioid agonist/placebo in combination with non-therapeutic, experimental doses of active sedative/placebo. Opioid/placebo and sedative/placebo doses will be administered once during each session. It is possible to receive both active drugs on the same day. Opioid and sedative doses will be administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Opioid Agonist</intervention_name>
    <description>Active opioid agonist or placebo, administered orally</description>
    <arm_group_label>Opioid agonist/sedative</arm_group_label>
    <arm_group_label>Oral opioid agonist</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sedatives</intervention_name>
    <description>Active sedative or placebo, administered orally</description>
    <arm_group_label>Opioid agonist/sedative</arm_group_label>
    <arm_group_label>Oral sedative</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults, ages 18-55

          -  Current non-medical use of opioids and sedatives

        Exclusion Criteria:

          -  Physical dependence on opioids, alcohol, or benzodiazepines/sedatives/hypnotics

          -  Seeking treatment for drug use

          -  Significant medical problems
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon L Walsh, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Konnor QX Long, B.S.</last_name>
    <phone>859-257-4581</phone>
    <email>konnor@uky.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Nuzzo, M.A.</last_name>
    <phone>859-323-0002</phone>
    <email>pnuzz2@email.uky.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center on Drug and Alcohol Research</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul A Nuzzo, M.A.</last_name>
      <phone>859-323-0002</phone>
      <email>pnuzz2@email.uky.edu</email>
    </contact>
    <investigator>
      <last_name>Konnor QX Long, B.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sharon L Walsh, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2020</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Sharon Walsh</investigator_full_name>
    <investigator_title>Director, Center on Drug and Alcohol Research</investigator_title>
  </responsible_party>
  <keyword>opioid</keyword>
  <keyword>sedative</keyword>
  <keyword>opiate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypnotics and Sedatives</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We have no plans to share individual participant data with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

